Series A · Biotech · Geneva, Switzerland · Founded 2024 · 11–50 employees
Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for treating neurological disorders, spun out from Addex Therapeutics in 2024. The company secured a significant $63 million Series A funding round led by Perceptive Advisors to accelerate development of their preclinical assets. Their lead drug candidate is a selective muscarinic M4 positive allosteric modulator for schizophrenia treatment, alongside an mGlu7 negative allosteric modulator program. The company leverages a proven allosteric modulator drug discovery platform that offers greater selectivity and precision in targeting challenging neurological conditions compared to traditional approaches.
No open roles listed right now.